GH insider trading
HealthcareGuardant Health, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Company website: guardanthealth.com
GH insider activity at a glance
FilingIQ has scored 2,137 insider transactions for GH since Oct 9, 2018. The most recent filing in our index is dated May 12, 2026.
Across the full history, 32 open-market purchases
and 915 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GH insider trades is 59.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GH Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding GH
Frequently asked
- How many insider trades does FilingIQ track for GH?
- FilingIQ tracks 2,137 Form 4 insider transactions for GH (Guardant Health, Inc.), covering filings from Oct 9, 2018 onwards. 169 of those were filed in the last 90 days.
- Are GH insiders net buyers or net sellers?
- Across the full Form 4 history for GH, 32 transactions (1%) were open-market purchases and 915 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GH insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GH in?
- Guardant Health, Inc. (GH) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $13.93B.
Methodology & sources
Every GH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.